Stefan Schwabe Selected Research

Viloxazine

1/2022	Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects.
12/2021	Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
11/2021	Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
7/2021	A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
2/2021	Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.
1/2021	Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
1/2021	A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
1/2021	Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
1/2020	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.
1/2020	A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Schwabe Research Topics

Disease

14	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2022 - 03/2019
3	Epilepsy (Aura) 01/2020 - 07/2003
1	Body Weight (Weight, Body) 12/2021
1	Cardiotoxicity 01/2021
1	Seizures (Absence Seizure) 01/2020
1	Nausea 02/2004
1	Paresthesia (Dysesthesia) 02/2004
1	Migraine Disorders (Migraine) 02/2004
1	Fatigue 02/2004

Drug/Important Bio-Agent (IBA)

11	ViloxazineIBA 01/2022 - 01/2020
3	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020 - 01/2004
3	Topiramate (Topamax)FDA LinkGeneric 02/2004 - 07/2003
2	Molindone (Molindone Hydrochloride)FDA Link 01/2021 - 03/2019
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 02/2021
1	Serotonin ReceptorsIBA 02/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 01/2021
1	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA 01/2021
1	Pharmaceutical PreparationsIBA 10/2020
1	Serotonin (5 Hydroxytryptamine)IBA 01/2020
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020
1	Oxcarbazepine (Trileptal)FDA LinkGeneric 01/2020
1	Lamotrigine (Lamictal)FDA LinkGeneric 07/2003

Therapy/Procedure

3	Therapeutics 01/2020 - 07/2003